Cargando…

11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome

CONTEXT: Polycystic ovary syndrome (PCOS) is common and diagnosis requires an elevated testosterone. The clinical importance of adrenal 11-oxyandrogens in PCOS is unclear. OBJECTIVE: We sought to determine if 11-oxyandrogens 1) better identify PCOS diagnosis compared to testosterone, 2) predict clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Anya E, Ware, Meredith A, Breslow, Emily, Pyle, Laura, Severn, Cameron, Nadeau, Kristen J, Chan, Christine L, Kelsey, Megan M, Cree-Green, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123281/
https://www.ncbi.nlm.nih.gov/pubmed/35611324
http://dx.doi.org/10.1210/jendso/bvac037
_version_ 1784711520114966528
author Taylor, Anya E
Ware, Meredith A
Breslow, Emily
Pyle, Laura
Severn, Cameron
Nadeau, Kristen J
Chan, Christine L
Kelsey, Megan M
Cree-Green, Melanie
author_facet Taylor, Anya E
Ware, Meredith A
Breslow, Emily
Pyle, Laura
Severn, Cameron
Nadeau, Kristen J
Chan, Christine L
Kelsey, Megan M
Cree-Green, Melanie
author_sort Taylor, Anya E
collection PubMed
description CONTEXT: Polycystic ovary syndrome (PCOS) is common and diagnosis requires an elevated testosterone. The clinical importance of adrenal 11-oxyandrogens in PCOS is unclear. OBJECTIVE: We sought to determine if 11-oxyandrogens 1) better identify PCOS diagnosis compared to testosterone, 2) predict clinical comorbidities of PCOS, and 3) are altered with an combined oral contraceptive pill (COCP) or metformin therapy. METHODS: Data from 200 adolescent female participants aged 12 to 21 years, most with obesity, enrolled across 6 studies in pediatric endocrinology were included: 70 non-PCOS controls, 115 untreated PCOS, 9 PCOS + obesity treated with COCP, and 6 PCOS + obesity treated with metformin. 11-Hydroxyandrostenedione (11-OHA4), 11-hydroxytestosterone (1-OHT), 11-ketotestosterone (11-KT), and testosterone were measured with liquid chromatography–tandem mass spectrometry. Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. RESULTS: Untreated girls with PCOS had higher 11-OHA4 (P = .003) and 11-OHT (P = .005) compared to controls, but not 11-KT (P = .745). Elevated 11-OHA4 remained statistically significant after controlling for obesity. Testosterone better predicted PCOS status compared to 11-oxyandrogens (receiver operating characteristic curve analysis: 11-OHA4 area under the curve [AUC] = 0.620, 11-OHT AUC = 0.638; testosterone AUC = 0.840). Among untreated PCOS patients, all 3 11-oxyandrogens correlated with hirsutism severity. 11-KT (P = .039) and testosterone (P < .006) were lower in those on COCP treatment compared to untreated PCOS. Metformin treatment had no effect on 11-oxyandrogens, although testosterone was lower (P = .01). CONCLUSION: Although 11-oxyandrogens do not aid in the diagnosis of PCOS, they relate to excess hair growth. COCP treatment may related to 11-KT; however, further work is needed to determine causality, relationship with metabolic outcomes, and the clinical utility of measuring these androgens in PCOS.
format Online
Article
Text
id pubmed-9123281
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91232812022-05-23 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome Taylor, Anya E Ware, Meredith A Breslow, Emily Pyle, Laura Severn, Cameron Nadeau, Kristen J Chan, Christine L Kelsey, Megan M Cree-Green, Melanie J Endocr Soc Clinical Research Article CONTEXT: Polycystic ovary syndrome (PCOS) is common and diagnosis requires an elevated testosterone. The clinical importance of adrenal 11-oxyandrogens in PCOS is unclear. OBJECTIVE: We sought to determine if 11-oxyandrogens 1) better identify PCOS diagnosis compared to testosterone, 2) predict clinical comorbidities of PCOS, and 3) are altered with an combined oral contraceptive pill (COCP) or metformin therapy. METHODS: Data from 200 adolescent female participants aged 12 to 21 years, most with obesity, enrolled across 6 studies in pediatric endocrinology were included: 70 non-PCOS controls, 115 untreated PCOS, 9 PCOS + obesity treated with COCP, and 6 PCOS + obesity treated with metformin. 11-Hydroxyandrostenedione (11-OHA4), 11-hydroxytestosterone (1-OHT), 11-ketotestosterone (11-KT), and testosterone were measured with liquid chromatography–tandem mass spectrometry. Data between 1) untreated PCOS and controls and 2) untreated PCOS and the 2 treatment groups were compared. RESULTS: Untreated girls with PCOS had higher 11-OHA4 (P = .003) and 11-OHT (P = .005) compared to controls, but not 11-KT (P = .745). Elevated 11-OHA4 remained statistically significant after controlling for obesity. Testosterone better predicted PCOS status compared to 11-oxyandrogens (receiver operating characteristic curve analysis: 11-OHA4 area under the curve [AUC] = 0.620, 11-OHT AUC = 0.638; testosterone AUC = 0.840). Among untreated PCOS patients, all 3 11-oxyandrogens correlated with hirsutism severity. 11-KT (P = .039) and testosterone (P < .006) were lower in those on COCP treatment compared to untreated PCOS. Metformin treatment had no effect on 11-oxyandrogens, although testosterone was lower (P = .01). CONCLUSION: Although 11-oxyandrogens do not aid in the diagnosis of PCOS, they relate to excess hair growth. COCP treatment may related to 11-KT; however, further work is needed to determine causality, relationship with metabolic outcomes, and the clinical utility of measuring these androgens in PCOS. Oxford University Press 2022-03-09 /pmc/articles/PMC9123281/ /pubmed/35611324 http://dx.doi.org/10.1210/jendso/bvac037 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research Article
Taylor, Anya E
Ware, Meredith A
Breslow, Emily
Pyle, Laura
Severn, Cameron
Nadeau, Kristen J
Chan, Christine L
Kelsey, Megan M
Cree-Green, Melanie
11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title_full 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title_fullStr 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title_full_unstemmed 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title_short 11-Oxyandrogens in Adolescents With Polycystic Ovary Syndrome
title_sort 11-oxyandrogens in adolescents with polycystic ovary syndrome
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123281/
https://www.ncbi.nlm.nih.gov/pubmed/35611324
http://dx.doi.org/10.1210/jendso/bvac037
work_keys_str_mv AT tayloranyae 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT waremereditha 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT breslowemily 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT pylelaura 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT severncameron 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT nadeaukristenj 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT chanchristinel 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT kelseymeganm 11oxyandrogensinadolescentswithpolycysticovarysyndrome
AT creegreenmelanie 11oxyandrogensinadolescentswithpolycysticovarysyndrome